Abstract Purpose: To describe the Food and Drug Administration (FDA) review and approval
of erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally …

Introduction: Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor that
significantly increases survival for patients with previously treated advanced non-small cell …

Purpose This is a phase II, multicenter, open-label study of chemotherapy-naïve patients
with non–small-cell lung cancer (NSCLC) and age≥ 70 years who were treated with …

Background In the placebo-controlled phase III SATURN study, maintenance erlotinib after
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …

Abstract Learning Objectives After completing this course, the reader will be able to:
Evaluate the relationship between EGFR mutation status and clinical outcomes reported in …

Purpose Sorafenib, an oral multikinase inhibitor, has shown preliminary activity in non–small-
cell lung cancer (NSCLC). Patients with advanced NSCLC were treated with erlotinib with or …

7011 Background: Tarceva™(erlotinib) is a potent reversible HER1/EGFR tyrosine kinase
inhibitor with single-agent antitumor activity. TRIBUTE was a prospective, placebo-controlled …

Background A clinical trial that compared erlotinib with a placebo for non–small-cell lung
cancer demonstrated a survival benefit for erlotinib. We used tumor-biopsy samples from …

BACKGROUND:: Erlotinib is an oral tyrosine kinase inhibitor, 1026 targeting the human
epidermal receptor type 1/epidermal growth factor receptor, recently approved by the US …

Introduction BR. 21 demonstrated significant survival benefit for non-small cell lung cancer
patients receiving erlotinib compared with placebo. We undertook to characterize, by …